Table 1.
Analytical and in vitro activity data for mSH analogs.
| Peptide | Composition | MW Calc/Found | RT [min] | EC50 [nM] TREX-hFpn-GFP cells |
|---|---|---|---|---|
| PR73 | C86H133N21O15S | 1733.19/1734.34 | 47.11* | 4.2±0.3 |
| mHS1 | C46H69N15O9S3 | 1072.32/1072.85 | 29.47 | >600 |
| mHS2 | C52H77N17O11S3 | 1212.47/1212.20 | 28.06 | >600 |
| mHS3 | C50H75N15O11S4 | 1190.47/1190.96 | 29.24 | >600 |
| mHS4 | C54H75N15O9S3 | 1174.46/1174.73 | 33.42 | 585.6±71.1 |
| mHS5 | C54H75N15O9S3 | 1174.46/1174.86 | 34.19 | 272.2±18.9 |
| mHS6 | C54H75N15O9S3 | 1174.46/1174.60 | 34.18 | 598.9±114.2 |
| mHS7 | C53H74N16O9S3 | 1175.45/1175.90 | 27.65 | >600 |
| mHS8 | C58H77N15O9S3 | 1224.52/1225.92 | 30.95 | >600 |
| mHS9 | C60H79N15O10S3 | 1266.56/1266.74 | 39.58 | 477.4±76.3 |
| mHS10 | C61H81N15O9S3 | 1264.58/1264.52 | 41.14 | 516.9±131.7 |
| mHS11 | C96H134N28O16S5 | 2096.59/2097.25 | 34.74 | >600 |
| mHS12 | C138H193N41O23S7 | 3018.73/3018.75 | 34.00/34.89 | >600 regioisomers |
| mHS13 | C141H199N41O31S7 | 3188.80/3188.87 | 34.33 | >600 |
| mHS14 | C60H85N17O13S3 | 1348.62/1348.85 | 30.44 | 531.7±36.1 |
| mHS15 | C60H79N15O9S3 | 1250.56/1250.82 | 36.16 | 54.3±2.7 |
| mHS16 | C66H89N17O13S3 | 1424.71/1425.16 | 32.47 | 75.1±0.3 |
| mHS17 | C86H128N18O12S3 | 1702.25/1702.26 | 58.73 | 44.2±6.8 |
| mHS18 | C53H69N13O7S3 | 1096.39/1096.45 | 40.94 | 103.8±13.0 |
| mHS19 | C59H73N13O7S3 | 1172.49/1172.74 | 45.16 | 112.7±10.5 |
| mHS20 | C53H69N13O7S3 | 1096.39/1096.61 | 41.01 | 335.3±41.2 |
| mHS21 | C52H68N12O6S3 | 1053.36/1053.87 | 44.03 | 268.8±29.2 |
| mHS22 | C66H92N16O11S3 | 1381.73/1381.51 | 38.32 | 164.5±14.7 |
| mHS23 | C64H89N15O10S3 | 1324.68/1324.28 | 40.54 | 92.3±19.5 |
| mHS24 | C74H107N15O9S3 | 1446.93/1446.57 | 50.68* | >600 |
| mHS25 | C73H106N14O8S3 | 1403.91/1403.63 | 50.73* | 369.0±35.0 |
| mHS26 | C75H112N14O10S3 | 1465.98/1466.43 | 55.52* | 52.3±10.8 |
| mHS27 | C68H99N13O7S3 | 1306.79/1306.43 | 57.32* | >600 |
| mHS28 | C68H99N13O7S3 | 1306.79/1306.90 | 57.72* | 458.3±87.7 |
Analytical RP-HPLC was performed on a Varian ProStar 210 HPLC system equipped with ProStar 325 Dual Wavelength UV-Vis detector with the wavelengths set at 220 nm and 280 nm (Varian Inc., Palo Alto, CA). Mobile phases consisted of solvent A, 0.1% TFA in water, and solvent B, 0.1% TFA in acetonitrile. Analyses of peptides were performed with an analytical reversed-phase C18 SymmetryShield™ column, 4.6×250 mm, 5 μm (Waters, Milford, MA) or (*) an analytical reversed-phase C4 XBridge™ BEH300 column, 4.6×150 mm, 3.5 μm (Waters, Milford, MA), applying linear gradient of solvent B from 0 to 100% over 100 min (flow rate: 1 ml/min).